CCR1 expression levels in stage I and II ovarian cancer patients showed a significant difference in median progression free survival of 37 months with high CCR1 compared to 96 months with low CCR1 expression (HR 2.13; p = 0.032) (Fig. 5h, i). Here, CCR1 is linked to ovarian carcinoma.